CTOs on the Move

Cornerstone Specialty Network

www.cornerstoneoncology.com

 
Cornerstone Specialty Network is a company that provides value to community-based oncology practices through network aggregation, delivering value-added opportunities that support independence and long-term sustainability for community oncology practices.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Healthcare Distribution Management Association

Healthcare Distribution Management Association is a Arlington, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sinai Residences

Sinai Residences is a retirement community in Boca Raton that offers luxurious surroundings and a culture of sophistication. They provide top-notch independent and assisted living, memory care, rehab, and skilled nursing services on site.

Union Pacific RR Employes Health Systems

Union Pacific RR Employes Health Systems is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dentalcorp

dentalcorp is Canada`s largest network of dental practices, committed to advancing the overall well-being of Canadians by aiming to deliver the best clinical outcomes and unforgettable experiences. dentalcorp acquires leading dental practices, uniting them in a common goal: to be Canada`s most trusted healthcare network. Leveraging its industry-leading technology, know-how and scale, dentalcorp offers professionals the unique opportunity to retain their clinical autonomy while unlocking their potential for future growth. dentalcorp provides world-class resources to Partners including Talent & Recruitment, Human Resources, Training & Development, Legal & Compliance, Practice Optimization, Marketing, IT, Procurement, Finance, AP, and Payroll. We enable the best to be even better.

Immune Pharmaceuticals

Immune Pharmaceuticals applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The Company’s lead product candidate, bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma. The Company is evaluating the use of its NanomAb® platform, a second generation antibody drug conjugate technology, with chemotherapeutics in order to enhance their safety and efficacy profiles by delivering the medicines directly to cancer cells. The Company’s growing oncology pipeline also includes proprietary antibodies and, clinical-stage small molecules that have been shown activity in a variety of solid tumors. Immune is headquartered in the U.S., with its primary research and development facilities in Israel.